Status: Recruiting
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.
Participants needed: 84
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: NMD Pharma A/SUpdated: Jul 1, 2026Locations: 40
Eligibility criteria
Participant must be a male or female being 18 or more, at the time of signing th... [+6]
Known medical or psychological condition(s) or risk factor that, in the opinion... [+4]